1-4 of 4
Rajeshwari Sridhara
Close
Sort by
Journal Articles

FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens

Bindu Kanapuru, MD, Susan Jin, Kunthel By, Theresa Carioti, Yuan-Li Shen, PhD, Rajeshwari Sridhara, PhD, Nicole J Gormley, MD, Ann T. Farrell, MD, Richard Pazdur, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3194.
https://doi.org/10.1182/blood-2019-127141
Published: 2019
Journal Articles

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Kelly J. Norsworthy, MD, Xin Gao, PhD, Chia-Wen Ko, PhD, Jiaxi Zhou, MS, Yutao Gong, PhD, Yuan Li Shen, PhD, Rajeshwari Sridhara, PhD, Albert B. Deisseroth, MD PhD, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2670.
https://doi.org/10.1182/blood-2018-99-119678
Published: 2018
Journal Articles

Poor ESA Responders As Defined By Week 4 Hemoglobin Response Have Greater ESA Dosing but Worse Cardiovascular Outcomes in Patients with Anemia of Chronic Kidney Disease (CKD) Not on Dialysis

Robert C. Kane, MD, Qing Xu, PhD, Rajeshwari Sridhara, PhD, Justin Earp, PhD
Journal: Blood
Blood (2014) 124 (21): 4016.
https://doi.org/10.1182/blood.V124.21.4016.4016
Published: 2014
Journal Articles

Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia

Albert Deisseroth, Ann Farrell, Robert Justice, Robert Kane, Rajeshwari Sridhara, Huanyu Chen, Kun He, Richard Pazdur
Journal: Blood
Blood (2010) 115 (2): 430.
https://doi.org/10.1182/blood-2009-09-244236
Published: 2010